The synergistic action of IL-17 with TNF-α has been shown to have major pro-coagulant and pro-thrombotic effects [17,18], and furthermore, combined blockade of TNF-α and IL-17 has been shown to be a safe treatment strategy in autoimmune diseases where monotherapy is not fully effective [19]. Here, TNF is linked to autoimmune disease.